CN-122012314-A - Novel intestinal probiotics butyric acid monad and application thereof

Abstract

The invention discloses a novel intestinal probiotics butyric acid monad and application thereof, the strain is preserved in the microorganism strain collection of Guangdong province, the preservation number is GDMCC No. 67648, and the invention proves that butyric acid monad (Butyricimonas virosa) can promote the synthesis of TMP in the intestines through remodelling the intestinal canal and then is converted into thiamine through a mouse model. Thiamine accumulates in the liver through the intestinal liver circulation and is further converted to TPP. This process promotes degradation of BCAAs and further regulates liver lipid metabolism, significantly alleviating the progression of fatty liver disease associated with metabolic dysfunction induced by a high-fat diet.

Inventors

• LI SHANGYONG
• ZOU YUANQIANG
• HE NINGNING
• YANG ZIZHEN
• WANG HAOYU

Assignees

• 青岛大学
• 深圳华大生命科学研究院

Dates

Publication Date

20260512

Application Date

20260119

Claims (10)

1. 1. A butyric acid single cell strain AM16-14, characterized in that the butyric acid single cell strain AM16-14 was deposited at the collection of microorganism strains in the province of guangdong at 1 month 14 of 2026 under accession number GDMCC No. 67648.
2. 2. A composition comprising the pseudomonas butyrate AM16-14 as defined in claim 1.
3. 3. Use of a butyric acid monorail AM16-14 according to claim 1 or a composition according to claim 2 for the preparation of a medicament for the prevention and/or treatment of obesity and metabolic dysfunction related fatty liver disease (MASLD).
4. 4. Use according to claim 3, characterized in that the medicament is capable of promoting the biosynthesis of thiamine or its precursor TMP in the intestine.
5. 5. The use according to claim 3, wherein the medicament is capable of increasing the level of thiamine pyrophosphate (TPP) in liver tissue.
6. 6. The use according to claim 3, wherein the medicament is capable of promoting activation of the hepatic branched chain alpha-keto acid dehydrogenase complex (BCKDH).
7. 7. The use according to claim 3, wherein the medicament is capable of reducing Branched Chain Amino Acid (BCAAs) levels in liver tissue.
8. 8. A health food comprising the bacterial cells of the butyric acid monomonas AM16-14 according to claim 1, a fermentation broth thereof, a fermentation product thereof, or the composition according to claim 2, and a pharmaceutically acceptable adjuvant.
9. 9. A medicament comprising the bacterial cell of pseudomonas butyrate AM16-14, a fermentation broth thereof, a fermentation product thereof, or the composition of claim 2 of claim 1, and a pharmaceutically acceptable carrier.
10. 10. The medicament according to claim 9, wherein the dosage form of the medicament is an oral formulation.

Description

Novel intestinal probiotics butyric acid monad and application thereof Technical Field The invention belongs to the technical field of microbial medicines, and particularly relates to novel intestinal probiotics butyric acid single-cell and application thereof in treating obesity and metabolic dysfunction related fatty liver diseases. Background The disclosure of this background section is only intended to increase some understanding of the general background of the invention and is not necessarily to be construed as an admission or any form of suggestion that this information forms the prior art already known to those of ordinary skill in the art. Fatty liver disease (MASLD) related to metabolic dysfunction is the most common chronic liver disease worldwide, coexists with metabolic syndromes such as obesity, insulin resistance and the like, and the disease spectrum can progress from simple fatty liver to steatohepatitis, liver fibrosis and even cirrhosis. At present, no specific medicine directly aiming at MASLD pathological cores is clinically approved, first-line treatment still depends on life style intervention which is difficult to maintain for a long time, and huge unmet clinical needs exist. In recent years, the "gut-liver axis" theory provides a new perspective for MASLD's treatment. Dysbacteriosis in the intestinal tract can promote liver lipid accumulation and inflammation through a variety of pathways. Although some probiotics (e.g. lactobacillus, bifidobacterium strains) have been reported to have some effect of improving liver steatosis in animal models, their mechanism of action is mostly attributed to relatively indirect and non-specific pathways regulating intestinal barrier function, reducing systemic low-grade inflammation, etc. There is a general limitation in these studies in that they fail to directly correlate specific intestinal species with specific, verifiable metabolic regulation pathways within liver cells. Thus, the skilled artisan cannot predict whether or not there are and what intestinal strains will be able to precisely target and correct the metabolic disorders inherent in the liver. Of particular note, branched Chain Amino Acid (BCAAs) metabolic disorders have been demonstrated to be a key molecular bridge linking obesity, insulin resistance, and MASLD. The blockage of BCAAs catabolism in the liver leads to its abnormal accumulation, which directly interferes with lipid metabolism and promotes steatosis. The active form of thiamine (vitamin B1), thiamine pyrophosphate (TPP), is the key coenzyme that catalyzes the rate-limiting step in BCAAs decomposition. However, the scientific question of whether and how to regulate liver BCAAs breakdown and lipid homeostasis by affecting host thiamine metabolism is completely blank in the prior art. In other words, the art lacks a microbial formulation and its definite mechanism of action that is capable of treating MASLD by this clear, direct "enterobacteria-thiamine-liver BCAAs axis". Therefore, developing a novel probiotic strain with clear action mechanism and capable of directly interfering with the liver core metabolic pathway becomes an urgent technical problem for solving MASLD treatment bottleneck. Disclosure of Invention In order to overcome the defect that MASLD microbial therapeutic agents which can accurately target liver metabolic disorder and have a definite action mechanism are lacking in the prior art, the invention aims to provide a brand-new butyric acid single-cell strain, products such as a composition thereof and the like and specific application thereof. The technical scheme adopted by the invention is as follows: In a first aspect, the invention provides a strain of Pseudomonas butyrate (Butyricimonas virosa) AM16-14 deposited at the Cantonese microorganism strain collection at day 14 of 01 of 2026 under accession number GDMCC No. 67648 at accession number 5 building No. 59 of the university of road 100 in Guangzhou city martyr. The butyric acid single-cell strain AM16-14 is hereinafter referred to as butyric acid single-cell B. In a second aspect, the present invention provides a composition comprising the pseudomonas butyrate b. Further, the live bacteria amount of the butyric acid single cell B. Virosa contained in the above composition is not less than 1X 10 6 cfu/g. Further, the composition is a microbial inoculum, and the butyric acid single cell B. Virosa is prepared into a microecological solution preparation or a freeze-dried bacterial powder preparation after fermentation culture, bacterial body collection and mixing with a protective agent. In a third aspect, the present invention provides the use of a single butanoic acid bacterium b, virosa as described in the first aspect or a composition as described in the second aspect for the preparation of a product for the prevention and/or treatment of obesity and metabolic dysfunction related fatty liver disease (MASLD). Further, in such applications, the st